Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study is a research paper published in The Journal of Prevention of Alzheimer s Disease (2024). On theSindex it has a DataRank of 0.360. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →NIA NIH HHS
Grant: P30 AG062421
NIA NIH HHS
Grant: R01 AG063689
NIA NIH HHS
Grant: U19 AG010483
National Institutes of Health
Grant: 3U24AG057437-02S1
Alzheimers Clinical Trials Consortium (ACTC)
National Institutes of Health
Grant: 5R01AG063689-02
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension Study
National Institutes of Health
Grant: 3U19AG010483-26S4
Alzheimer's Disease Cooperative Study
Fields of Study
MeSH Terms
Keywords